Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific Inc. (TMO - Free Report) one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its promising first-quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.42 per share. Thermo Fisher’s adjusted earnings per share of $2.50 is up 20% year-over-year in the reported quarter.
Revenues: Thermo Fisher posted first quarter revenues of $5.85 billion, which has also surpassed the Zacks Consensus Estimate for revenues of $5.63 billion.
Key Stats: Among its four business segments in the reported quarter, Thermo Fisher delivered revenues of $1.50 billion (up 10%) in Life Sciences Solutions, $1.26 billion (up 19%) in Analytical Instruments, $0.95 billion (up 9%) in Specialty Diagnostics and $2.41 billion (up 42%) in Laboratory Products and Services respectively.
Major Factors: Management is pleased with the way the company has started the year 2018. The company launched innovative new products in the key technology platforms, and enabled breakthroughs in proteomics, genetic analysis and structural biology. The company also gained from high-growth emerging markets, particularly China, India and South Korea.
Stock Price: Following the earnings release, share prices gained 0.6% in the pre-market trading session.
Check back later for our full write up on this Thermo Fisher earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific Inc. (TMO - Free Report) one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #3 (Hold) but that could change following its promising first-quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.42 per share. Thermo Fisher’s adjusted earnings per share of $2.50 is up 20% year-over-year in the reported quarter.
Revenues: Thermo Fisher posted first quarter revenues of $5.85 billion, which has also surpassed the Zacks Consensus Estimate for revenues of $5.63 billion.
Key Stats: Among its four business segments in the reported quarter, Thermo Fisher delivered revenues of $1.50 billion (up 10%) in Life Sciences Solutions, $1.26 billion (up 19%) in Analytical Instruments, $0.95 billion (up 9%) in Specialty Diagnostics and $2.41 billion (up 42%) in Laboratory Products and Services respectively.
Major Factors: Management is pleased with the way the company has started the year 2018. The company launched innovative new products in the key technology platforms, and enabled breakthroughs in proteomics, genetic analysis and structural biology. The company also gained from high-growth emerging markets, particularly China, India and South Korea.
Stock Price: Following the earnings release, share prices gained 0.6% in the pre-market trading session.
Check back later for our full write up on this Thermo Fisher earnings report later!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TMO - FREE